Javad Shahidi - 01 Apr 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Medical Officer
Signature
s/ Marella Thorell, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
01 Apr 2022
Net transactions value
$0
Form type
4
Filing time
04 Apr 2022, 18:00:17 UTC
Previous filing
15 Mar 2022
Next filing
06 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Award $0 +330,000 $0.000000 330,000 01 Apr 2022 Ordinary Shares 330,000 $9.08 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to such option shall vest and become exercisable on April 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.